Your fast, high-signal look at everything that moved biotech, medtech, and pharma today. The BioMed Nexus Daily Update delivers the most important regulatory moves, trial readouts, deals, and industry developments in one concise, easy-to-scan report. Updated every weekday morning.
Biotech opened the week navigating extreme regulatory volatility and clinical performance divergence. uniQure suffered a devastating 49% share collapse after the FDA reversed course on
Biotech delivered a sobering Halloween eve session as regulatory concerns collided with policy reforms and M&A speculation. Intellia Therapeutics’ CRISPR programs hit an FDA clinical
Healthcare markets delivered a news-heavy session today as mega-deals, regulatory shifts, and compelling clinical data converged to reshape sector dynamics. Thermo Fisher Scientific’s $8.9 billion
Monday delivered a mixed but ultimately positive session for healthcare investors, with strong pharmaceutical earnings and strategic deals offsetting concerns about biotech funding headwinds. Biopharma
Explore the latest biotech innovations from October 6-13, 2025: AstraZeneca’s oncology trials, FDA approvals for IPF and CSCC, allogeneic CAR-NK cells, and trends in direct-to-consumer
Genmab acquires Merus for $8B, FDA approves Alzheimer’s blood test, and Trump Administration secures drug pricing deals. Complete biotech industry analysis. 1. Genmab’s $8 Billion
The final week of September brought seismic shifts across the pharmaceutical and biotechnology sectors, with an $8 billion oncology acquisition, leadership changes at Big Pharma
The pharmaceutical industry’s marketing playbook is about to get a major rewrite. The FDA has announced an aggressive campaign against misleading drug advertisements, signaling the
Concord Biotech Plummets: Shares crashed 27% by Feb 14, capping a brutal week after a failed trial sank hopes—smallcap biotech’s reeling. Economic Times calls it
Latent Labs Unveils AI: On Feb 13, Latent Labs launched an AI platform targeting proteins and RNA for drug discovery, boasting 30% faster hit rates.
